Two Sigma Securities’s Virax Biolabs VRAX Stock Holding History

Two Sigma Securities’s Portfolio VRAX Stock Details VRAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-545	Closed	-$15.5K	–	2138
2025 Q1	$15.5K	Buy	+545	New	+$24K	﹤0.01%	1148
2023 Q3	–	Sell	-73	Closed	-$7.08K	–	3531
2023 Q2	$7.08K	Sell	73 -26	-26%	-$2.86K	﹤0.01%	2636
2023 Q1	$17.2K	Buy	+99	New	+$19.2K	﹤0.01%	2382

Other funds holding VRAX

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return

Two Sigma Securities's VRAX Position: Q2 2025 in Review

Two Sigma Securities sold out of Virax Biolabs (VRAX) in Q2 2025, closing a stake of 545 shares — an estimated $15.5K sold.

Two Sigma Securities first reported a position in VRAX in Q1 2023 and held it in 3 quarters. The position peaked at $17.2K in Q1 2023. 2 funds tracked by Wall St. Rank hold VRAX as of Q2 2025.

Two Sigma Securities reported no remaining Virax Biolabs position as of Q2 2025 after selling out during the quarter.
Two Sigma Securities sold 545 Virax Biolabs shares in Q2 2025, an estimated $15.5K.
Two Sigma Securities first reported a position in Virax Biolabs in Q1 2023 and held it in 3 quarters.
Two Sigma Securities's Virax Biolabs position peaked at $17.2K in Q1 2023.
2 funds tracked by Wall St. Rank held Virax Biolabs as of Q2 2025.

Based on Two Sigma Securities's 13F filing for Q2 2025, filed 14 Aug 2025.